X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

AKRO

Closed

Akero Therapeutics Inc

51.41
-1.95 (-3.65%)
Last Update: 01 Jul 2025 23:26:00
Yesterday: 53.36
Day's Range: 51.12 - 53.8255
Send
When Written:
 
38.26
Akero Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing transformative treatments for serious metabolic diseases. The company's lead product candidate, AKR-001, is a long-acting fibroblast growth factor 21 (FGF21) analog that is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. AKR-001 has shown promising results in clinical trials, including a Phase 2a study in NASH patients, and is currently in Phase 2b clinical trials for NASH. Akero Therapeutics was founded in 2017 and is headquartered in South San Francisco, California.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X